
Your previous employer may have set a high standard. Executive coach Angela Justice explains how holding every company to it can distort your judgment and undermine your influence. hubs.li/Q04FF87F0

Your source for biopharma news and jobs

Your previous employer may have set a high standard. Executive coach Angela Justice explains how holding every company to it can distort your judgment and undermine your influence. hubs.li/Q04FF87F0

The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators. hubs.li/Q04FF7jS0

AstraZeneca has cut about 600 U.S. commercial jobs, while Calidi Biotherapeutics plans to reduce its workforce by about 67%. Charles River Laboratories is closing its Worcester site, affecting two jobs, and Tempest Therapeutics is down to one employee. hubs.li/Q04FxDBR0

After securing $2.1 billion this May, AI-driven drug designer Isomorphic Labs is back with more money—a lot more—securing the industry’s largest private fundraise ever. hubs.li/Q04Fxzst0

Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals. hubs.li/Q04FwvVr0

At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease. hubs.li/Q04Fv_gF0

Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia. hubs.li/Q04FvR120

A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio. hubs.li/Q04FvLXP0

It’s been a long road to financial stability for Genetix Biotherapeutics, the rebranded name of bluebird bio following its February 2025 sale to two private equity firms, but on Monday the biotech estimated full year 2026 sales will reach $500 million. hubs.li/Q04FtYMD0

Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells. hubs.li/Q04FtYyG0

Women held 29% of biotech board seats in fiscal 2025 but just 8.8% of CEO roles, highlighting uneven progress across industry leadership spots. hubs.li/Q04FtYfC0

Helus Pharma’s psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events. hubs.li/Q04FmGJ60

Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks. hubs.li/Q04Fnrzj0

The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie. hubs.li/Q04Fns0-0

As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago. hubs.ly/Q04Fm2vQ0

Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners. hubs.ly/Q04Fm1M60